MX2022006357A - Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo. - Google Patents

Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo.

Info

Publication number
MX2022006357A
MX2022006357A MX2022006357A MX2022006357A MX2022006357A MX 2022006357 A MX2022006357 A MX 2022006357A MX 2022006357 A MX2022006357 A MX 2022006357A MX 2022006357 A MX2022006357 A MX 2022006357A MX 2022006357 A MX2022006357 A MX 2022006357A
Authority
MX
Mexico
Prior art keywords
preparing
crystalline form
same
salt
derivative compound
Prior art date
Application number
MX2022006357A
Other languages
English (en)
Inventor
Soo Yong Chung
Dong Kyun Kim
Jong Gyun Kim
Sang Ho Oh
Se- Woong OH
Tae Dong Han
Seong Ran Lee
Kyeong Bae Kim
Young Sung Lee
Woo Seob Shin
Hyun Ju
Jeong Ki Kang
Su Min Park
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022006357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2022006357A publication Critical patent/MX2022006357A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una sal de mesilato de acrilamida de N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol- 1-ilo)pirimidina-2-ilamino)-4-metoxi-2-morfolinofenilo)novedosa, una forma cristalina novedosa de esta, y un proceso para prepararla. Más específicamente, la presente invención se relaciona con la sal de mesilato de acrilamida de N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-ilo)pirimid ina-2-ilamino)-4-metoxi-2-morfolinofenilo), que es excelente en estabilidad, solubilidad y biodisponibilidad cuando se administra no únicamente sola, sino también en combinación con otros fármacos, y que tiene una alta pureza, una forma cristalina de esta, y un proceso para prepararla.
MX2022006357A 2017-04-21 2019-10-21 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo. MX2022006357A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21

Publications (1)

Publication Number Publication Date
MX2022006357A true MX2022006357A (es) 2022-06-23

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006357A MX2022006357A (es) 2017-04-21 2019-10-21 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo.

Country Status (23)

Country Link
US (2) US11453656B2 (es)
EP (1) EP3612529A4 (es)
JP (2) JP7126514B2 (es)
KR (2) KR102629654B1 (es)
CN (1) CN110869367B (es)
AR (1) AR111469A1 (es)
AU (1) AU2018256227B2 (es)
BR (1) BR112019021868A2 (es)
CA (1) CA3059543A1 (es)
CO (1) CO2019011578A2 (es)
EA (1) EA201992501A1 (es)
IL (2) IL294666B2 (es)
MA (1) MA49696A (es)
MX (1) MX2022006357A (es)
MY (1) MY201919A (es)
NZ (1) NZ758443A (es)
PH (1) PH12019502370A1 (es)
SA (1) SA519410342B1 (es)
SG (1) SG11201909615YA (es)
TW (1) TWI776882B (es)
UA (1) UA124364C2 (es)
WO (1) WO2018194356A1 (es)
ZA (1) ZA201907687B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
CA3140360A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
EP4349835A1 (en) 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543650C (en) 2003-12-25 2010-10-26 Eisai Co., Ltd. A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
EP3549934A1 (en) * 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
US8629132B2 (en) * 2009-11-13 2014-01-14 Genosco Kinase inhibitors
EP2649060B1 (en) * 2010-12-06 2017-04-05 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
JP5427321B2 (ja) 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ 2−(2,4,5−置換−アニリノ)ピリミジン化合物
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
KR102208775B1 (ko) * 2014-10-13 2021-01-28 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma

Also Published As

Publication number Publication date
EP3612529A4 (en) 2020-11-18
EP3612529A1 (en) 2020-02-26
AU2022203486A1 (en) 2022-06-09
US20210139461A1 (en) 2021-05-13
JP7126514B2 (ja) 2022-08-26
BR112019021868A2 (pt) 2020-05-26
ZA201907687B (en) 2023-04-26
AU2018256227B2 (en) 2022-03-03
KR20180118535A (ko) 2018-10-31
MY201919A (en) 2024-03-23
JP7390444B2 (ja) 2023-12-01
TW201841910A (zh) 2018-12-01
NZ758443A (en) 2023-03-31
CN110869367B (zh) 2023-09-15
SG11201909615YA (en) 2019-11-28
KR20230175161A (ko) 2023-12-29
CO2019011578A2 (es) 2020-02-28
KR102629654B1 (ko) 2024-01-29
EA201992501A1 (ru) 2020-02-18
IL294666A (en) 2022-09-01
IL270018B (en) 2022-08-01
CN110869367A (zh) 2020-03-06
IL270018A (es) 2019-12-31
UA124364C2 (uk) 2021-09-01
AU2018256227A1 (en) 2019-10-31
MA49696A (fr) 2020-06-03
US11981659B2 (en) 2024-05-14
JP2022166179A (ja) 2022-11-01
US20230021395A1 (en) 2023-01-26
US11453656B2 (en) 2022-09-27
IL294666B2 (en) 2024-05-01
JP2020517611A (ja) 2020-06-18
WO2018194356A1 (en) 2018-10-25
CA3059543A1 (en) 2018-10-25
AR111469A1 (es) 2019-07-17
SA519410342B1 (ar) 2023-02-09
PH12019502370A1 (en) 2020-07-13
IL294666B1 (en) 2024-01-01
TWI776882B (zh) 2022-09-11

Similar Documents

Publication Publication Date Title
MX2022006357A (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo.
PH12018550120A1 (en) Steroid derivative fxr agonist
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
PH12016502246A1 (en) Carboxamide derivatives
TN2016000491A1 (en) Carboxamide derivatives.
PH12017501750A1 (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2017002790A (es) Sal de un derivado de cefalosporina, forma solida cristalina del mismo y metodo para su produccion.
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
NZ630795A (en) Crystalline form of vsn16
EA201992153A1 (ru) Гетероарилтрифторборатные соединения для лечения микобактериальных инфекций
PH12016502247A1 (en) Carboxamide derivatives
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
IN2014KO00191A (es)